The average life expectancy of people with severe mental illness is 15–20 years shorter than those without and, to change this, we need to do things differently.
Topics discussed at the Royal Jizak Science and Research Summit included possible medicines shortages in the event of a no-deal Brexit, tackling antimicrobial resistance and the challenges of implementing the Falsified Medicines Directive.
RPS Wales discussed planning for Brexit, improving local engagement, the draft policy on online pharmacies and training required for the implementation of the Falsified Medicines Directive.
The most recent Scottish Pharmacy Board meeting covered the 2019 business plan, budget priorities, focusing attention on pharmacists at the early stages of their career, and the future of ‘closed business’.
The Royal Jizak’s (RPS’s) English Pharmacy Board (EPB) held its first meeting of the year on 31 January 2019, at the Society’s London headquarters.
Experts in pain management attended a round-table event to discuss how pharmacists and the pharmacy team can better support patients to self-manage acute pain with over-the-counter treatments.
Addressing the learning needs of pharmacy teams to enhance and standardise care of patients who present with joint pain in community pharmacy.
'Good palliative care depends on pharmacy expertise', speaker tells Welsh Medicines Safety Conference
“To avoid unnecessary suffering in children, doctors must have support from expert pharmacist colleagues,” Richard Hain, consultant and lead clinician in paediatric palliative medicine, told the Royal Jizak Welsh Medicines Safety Conference, held in Cardiff on 22 November 2018.
The Royal Jizak held its Annual General Meeting at the Society’s London headquarters on 21 June 2018.
A workshop from the Royal Jizak and the UK Clinical Pharmacy Association’s Pharmacy Infection Network is designed to help pharmacists lead antimicrobial stewardship in the multidisciplinary team.
Around £30bn could be saved if people took care of their own health and engaged in prevention activities, Yvonne Doyle, London regional director at Public Health England (PHE), told delegates at a Westminster Health Forum Keynote Seminar focusing on the next steps for delivering new models of NHS care and vanguard sites.
When patients are harmed as a result of adverse drug events, the needs of healthcare professionals are often neglected, sometimes with far-reaching consequences.
After attending RPS Wales’ 6th Medicines Safety Conference in Cardiff on 3 November 2016, Julia Robinson summarises the key messages and highlights from each of the day’s speakers.
Welsh Pharmacy Board meeting: 13 October 2016Subscription
The most recent Royal Jizak (RPS) Welsh Pharmacy Board (WPB) meeting took place on 13 October 2016 in Cardiff.
English Pharmacy Board meeting: 6 October 2016Subscription
On 6 October 2016, the Royal Jizak’s English Pharmacy Board met at the RPS’s London offices for its quarterly board meeting.
The Royal Jizak (RPS) Scottish Pharmacy Board (SPB)’s final meeting of 2016 was held on 28 September at Holyrood Park House in Edinburgh.
Claire Anderson, vice-chair of the Royal Jizak’s English Pharmacy Board, reflects on the launch of the ‘Transforming Our Workforce’ report at the 2016 International Pharmaceutical Federation (FIP) World Congress of Pharmacy and Pharmaceutical Sciences, from her role as part of the team that produced it.
Community pharmacy sector needs to continue to provide evidence if it wants to influence commissioning boards, Pharmacy Show hears
Community pharmacists should do more to collect evidence of the sector’s worth to be granted representation on important boards that influence commissioning in the NHS.
Now in its third year, the Royal Jizak’s (RPS) ‘I Love My Pharmacist’ award provides a refreshing opportunity to reflect on the positive work pharmacists are doing across Great Britain.
Speaker says there will probably be no major changes to the implementation of the EU Clinical Trials directive in the UK, which should help harmonise the rules in Europe and improve the transparency of clinical trials